Evidence map›Paper›PMID 35517872›Full record

ArticleAmerican journal of preventive cardiology2022

Patient experiences align with the familial hypercholesterolemia global call to action.

Laney K Jones, Nicole Walters, Andrew Brangan, Catherine D Ahmed, Katherine A Wilemon, Gemme Campbell-Salome, Alanna K Rahm, Samuel S Gidding, Amy C Sturm

Abstract read
In one paragraph

Article in American journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laney K JonesGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.
Nicole WaltersGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.
Andrew BranganGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.
Catherine D AhmedFamily Heart Foundation, Pasadena, CA, United States of America.
Katherine A WilemonFamily Heart Foundation, Pasadena, CA, United States of America.
Gemme Campbell-SalomeGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.
Alanna K RahmGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.
Samuel S GiddingGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.
Amy C SturmGenomic Medicine Institute, Geisinger, Danville, PA, United States of America.

Funding

Identification Methods, Patient Activation, and Cascade Testing for FH: IMPACT-FHR01HL148246 · NHLBI · GEISINGER CLINIC · PI Ana Morales Reyes · 2019 to 2026
$5.2M
NHLBI NIH HHS R01 HL148246
6 · The paper itself

Abstract

Objective: To explore alignment of perspectives from individuals and families with familial hypercholesterolemia (FH) to the FH Global Call to Action recommendations. Methods: Interviews and focus groups were conducted with individuals and families with FH from multiple U.S. health systems and the Family Heart Foundation community to capture lived experiences and to identify barriers to diagnosis, cascade testing, and treatment. Participant perspectives were examined and classified, according to their alignment to recommendations of the FH Global Call to Action. Results: A total of 75 lived experiences were analyzed. Participants were majority female, mostly white, older, and well-educated. Participants most frequently mentioned recommendations were family-based care (84%) and screening, testing, & diagnosis (84%), followed by treatment (69%), advocacy (60%), cost & value (59%), awareness (56%), research & registries (43%), and severe & homozygous FH (11%). An average of 4.65 (SD 1.76) recommendations were mentioned. Conclusions: The FH Global Call to Action was driven by the persistent unmet needs of those living with FH in receiving a timely diagnosis, appropriate care, and support to prevent early morbidity and mortality. Patient- and family-centric perspectives suggest the FH Global Call to Action captures these concerns. Acting on recommendations, particularly improvements in screening and family-based care, will address patient, and public health, concerns.

Indexed as

ASCVDASCVD, atherosclerotic cardiovascular diseaseFamilial hypercholesterolemiaFH, familial hypercholesterolemiaLDL-C, low-density lipoprotein cholesterolPrevention

Identifiers

PMID35517872
PMCPMC9061613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.